The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

By afschroeder • March 7, 2026

Leonhardt CS, Adham M, Bazarbashi S, Ben-Aharon I, Beets-Tan RGH, Boggi U, Brunner TB, Cellini F, Chiti A, Daamen L, De Bari B, De Dosso S, Ducreux M, Eng C, Falconi M, Ferrone CR, Frigerio I, Garajova I, Gerum S, Ghadimi M, Gruenberger T, Hammel P, Haustermans K, Hawkins M, He J, Heerkens HD, Huguet F, Intven MPW, Klaiber U, Kroese TE, Laurent-Puig P, Lordick F, Ludmir EB, Macarulla T, Matzinger O, Morganti AG, Mukherjee S, O'Reilly EM, Park JO, Papamichael D, Pfeiffer P, Ramia JM, Roeder F, Ruiz-García E, Satoi S, Scorsetti M, Schneider M, Seufferlein T, Serrablo A, Shrikhande SV, Smyth EC, Svrcek M, Takaori K, Tempero MA, Tissera NS, Tie J, Torres OJM, Turpin A, Van Cutsem E, Versteijne E, Vivaldi C, Wainberg ZA, Weichselbaum RR, Weitz J, Wolfgang CL, Prager GW, Strobel O. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Lancet Oncol. 2026 Mar;27(3):e141-e149. doi: 10.1016/S1470-2045(25)00714-4. PMID: 41785904.

Tags: Hematology/Oncology, Publications

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma

Colevas AD, Chin V, Park JJ, Adkins D, Phan M, Fang B, Forget F, Amorim J, Misiukiewicz K, Costa DA, Rainey N, Even C, Wong[...]

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study

Yu HA, Tang KH, Markovets AA, Hartmaier R, Smith PE, Cho BC, De Langen AJ, Goldberg SB, Goldman JW, Le X, Iwama E, Cosaert J,[...]